Date
2023-03-15- Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM
- The Pharmaceutical Industry Fellowship Program
provides physicians with the opportunity to experience the various steps of the
drug development process
Rockville, MD, Seoul, KR – March 15, 2023
HanAll
Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company
committed to discovering and developing innovative medicines for patients, is
now accepting applications for the 2023 pharmaceutical industry fellowship
program through April 15, 2023. The program is open to physicians trained in
Indonesia, who have a strong interest in working for a global biopharma
company.
The Pharmaceutical
Industry Fellowship Program, which runs from September 2023 to September 2025,
offers intensive training to grow into global drug development experts.
Participants will rotate every six months among four main arenas of drug
development including clinical development and project management, operations
and regulatory affairs, preclinical development and CMC, and business
development.
The
fellows will also receive education through DIA learning, experienced
mentoring, as well as hands-on experience working in a biopharmaceutical
company.
“Our
fellowship program fosters next generation research leaders contributing to
discovering and developing innovative therapies for patients. The fellows have
the opportunity to explore the wide range of roles and workstreams involved in
taking a therapy from discovery to commercialization and emerge positioned for
a variety of careers in biotechnology and pharma, while providing additional
layers of thoughts and perspectives to our team,” said Almira Chabi, M.D., Chief Medical Officer and Chief Development
Officer at HanAll.
Physicians based in Indonesia with strong English communication skills
are eligible to apply. Further information on required qualifications and how
to apply can be found at HanAll’s official LinkedIn page or the company website
(http://recruithpi.hanall.com).
About HanAll
Biopharma
HanAll Biopharma (KRX: 009420.KS) is a global
biopharmaceutical company founded in 1973, with the mission of making
meaningful contributions to patients’ lives by introducing innovative,
impactful therapies to address severe unmet medical needs. HanAll has been
operating a portfolio of pharmaceutical products in areas ranging from
endocrine, circulatory, and urologic diseases for more than 49 years.
HanAll has expanded its focus to ophthalmology,
immunology, oncology and neurology to discover and develop innovative medicines
for patients with diseases for which there are no effective treatments. Its lead
pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed
in Phase 3 and Phase 2 trials across the world for the treatment of rare
autoimmune disorders including myasthenia gravis, thyroid eye disease, warm
autoimmune hymolytic anemia, neuromyelitis optica, and immune thrombocytopenia.
Another main asset, HL036 (INN: tanfanercept), an anti-TNF alpha biologic, is being
evaluated in Phase 3 clinical trials in the US and China for the treatment of
dry eye disease. For further information connect with us on linkedIn or Instagram.
For any media inquiries, please contact HanAll PR/IR (pr@hanall.com, ir@hanall.com).
Disclaimer statement
The contents of this
announcement include statements that are, or may be deemed to be,
“forward-looking statements.” These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
“believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” or
“should” and include statements HANALL (the company, we) makes concerning its 2023
business and financial outlook and related plans; the
therapeutic potential of its product candidates; the intended results of its
strategy and the company, and its collaboration partners’, advancement of, and
anticipated clinical development, data readouts and regulatory milestones and
plans, including the timing of planned clinical trials and expected data
readouts; the design of future clinical trials and the timing and outcome of
regulatory filings and regulatory approvals. By their nature, forward-looking
statements involve risks and uncertainties, and readers are cautioned that any
such forward-looking statements are not guarantees of future performance. The
company’s actual results may differ materially from those predicted by the
forward-looking statements as a result of various important factors our
expectations regarding its the inherent uncertainties associated with
competitive developments, preclinical and clinical trial and product
development activities and regulatory approval requirements; our reliance on
collaborations with third parties; estimating the commercial potential of our
product candidates; our ability to obtain and maintain protection of
intellectual property for its technologies and drugs; our limited operating
history; and our ability to obtain additional funding for operations and to
complete the development and commercialization of its product candidates. A
further list and description of these risks, uncertainties and other risks can
be found in Korea Stock Exchange (KRX) filings and reports, including in our
most recent annual report as well as subsequent filings and reports filed by
the company with the KRX. Given these uncertainties, the reader is advised not
to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. We undertake no obligation to publicly update or revise the
information in this press release, including any forward-looking statements,
except as may be required by Korean law and regulations.